Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 07 - 12 symbols : LLY save search
Oncology (Cancer) / Hematologic Malignancies Approval Notifications
Published: 2021-07-12 (Crawled : 00:01) - fda.gov
LLY | $728.765 -2.3% 1.5M
|
Health Technology
|
| O: -0.98%
H: 1.2%
C: 0.36%
BMY | $48.58 0.58% 2.6M
|
Health Technology
|
| O: -0.15%
H: 1.19%
C: 0.66%
ADCT | $4.86 2.1% 120K
|
Health Technology
|
| O: -0.41%
H: 2.22%
C: -1.07%
YMAB | $14.955 -0.3% 120K
|
Health Technology
|
| O: 0.03%
H: 1.08%
C: -0.36%
SNY | News | $46.34 2.09% 620K
|
Health Technology
|
| O: 1.84%
H: 0.27%
C: -0.38%
REGN | $894.35 0.04% 140K
|
Health Technology
|
| O: -0.08%
H: 1.11%
C: -1.02%
KPTI | $1.255 -1.95% 460K
|
Health Technology
|
| O: 0.1%
H: 1.48%
C: -3.38%
INCY | $52.45 -0.7% 530K
|
Health Technology
|
| O: 0.0%
H: 0.49%
C: -1.05%
EPZM | $1.47 -1.34% 0.0%
|
Health Technology
|
| O: -0.26%
H: 1.09%
C: -0.52%
CLVS | $0.0812 -3.94%
|
Health Technology
|
| O: 5.35%
H: 0.7%
C: -7.18%
BPMC | News | $87.16 -1.96% 130K
|
Health Technology
|
| O: -0.21%
H: 0.05%
C: -2.51%
AVEO | $15.0 0.0% 0
|
Health Technology
|
| O: 1.47%
H: 0.0%
C: -5.79%
cancer approval
Valuation in Geriatric Medicines Market to Reach US$ 1142.8 Bn by 2027, Use in Managing Cardiovascular Diseases Spurs Growth: TMR
Published: 2021-07-12 (Crawled : 15:00) - prnewswire.com
PFE A | $25.81 1.65% 15M
|
Health Technology
|
| O: 0.13%
H: 1.49%
C: 0.25%
NVS | $93.815 1.35% 410K
|
Health Technology
|
| O: 0.5%
H: 0.28%
C: -0.24%
GSK | $39.605 0.85% 790K
|
Health Technology
|
| O: 0.22%
H: 0.94%
C: 0.3%
LLY | $728.765 -2.3% 1.5M
|
Health Technology
|
| O: -0.98%
H: 1.2%
C: 0.36%
BMY | $48.58 0.58% 2.6M
|
Health Technology
|
| O: -0.15%
H: 1.19%
C: 0.66%
SNY | News | $46.34 2.09% 620K
|
Health Technology
|
| O: 1.84%
H: 0.27%
C: -0.38%
disease cardiovascular growth cardio
Clinical Catch-Up: July 5-9
Published: 2021-07-12 (Crawled : 14:00) - biospace.com/
LLY | $728.765 -2.3% 1.5M
|
Health Technology
|
| O: -0.98%
H: 1.2%
C: 0.36%
Innovent Announces the First Patient Dosed in the Phase 1 Study of IBI323 (Anti-LAG-3/PD-L1 Bispecific Antibody) in Patients with Advanced Malignant Tumors
Published: 2021-07-12 (Crawled : 01:00) - prnewswire.com
LLY | $728.765 -2.3% 1.5M
|
Health Technology
|
| O: -0.98%
H: 1.2%
C: 0.36%
phase 1 antibody phase 2
Gainers vs Losers
| 77% | 23% |
Top 10 Gainers
AGBA | News | $1.22 205.0% 86M
|
Finance
NVFY | $3.45 63.51% 20M
|
Consumer Durables
EGOX | $0.054 50.0% 290M
|
CHRO | $1.66 35.51% 70K
|
n/a
INDO | $5.43 33.09% 10M
|
Energy Minerals
ZCMD | $1.86 28.28% 29M
|
Commercial Services
PAPL | $2.07 26.22% 550K
|
RWOD | $10.08 26.05% 5.6M
|
n/a
HUSA 4 | $2.07 23.95% 2.1M
|
Energy Minerals
TPET | $0.4001 22.02% 35M
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.